Sugi Predict

Sugi Predict / Compounds / SCHEMBL2993260

SCHEMBL2993260

SCHEMBL2993260

COc1cc2c(nc1OC)c(-c1cc3c(C(NCc4ccc(N5CCN(C)CC5)cc4)S(=O)(=O)c4ccc(C)cc4)ccnc3[nH]1)cn2C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 5/20 0.36
▸ IGF1R P08069 3/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ DYRK1B Q9Y463 2/20 0.35
▸ DYRK3 O43781 1/20 0.35
▸ CLK1 P49759 1/20 0.35
▸ CLK2 P49760 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ DYRK2 Q92630 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ DYRK4 Q9NR20 1/20 0.35
▸ EGFR P00533 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ CDK9 P50750 6/20 0.34
▸ CCNT1 O60563 5/20 0.34
▸ MAP4K1 Q92918 1/20 0.33
▸ TBK1 Q9UHD2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2990034 0.94 TBK1 (0.38) IGF1RCDK2CDK9CCNT1TBK1
SCHEMBL2989858 0.85 TBK1 (0.40) IGF1RCDK9CCNT1TBK1
SCHEMBL2996531 0.84 IGF1R (0.38) IGF1RCDK9CCNT1
SCHEMBL2994861 0.84 IGF1R (0.39) IGF1RCDK9CCNT1
SCHEMBL2988305 0.83 CCNT1 (0.36) IGF1RCDK9CCNT1
SCHEMBL2996398 0.83 IGF1R (0.38) IGF1RCDK9CCNT1
SCHEMBL2990420 0.82 IGF1R (0.40) IGF1RCDK9CCNT1
SCHEMBL2989320 0.81 IGF1R (0.38) IGF1REGFRCDK9CCNT1
SCHEMBL2989661 0.81 IGF1R (0.34) IGF1RCDK9CCNT1
SCHEMBL2993746 0.81 IGF1R (0.36) IGF1RCDK9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 — — US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 — — US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 — — US disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 — — EP disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 ALK 320/4885IGF1R 606/4885CDK2 3/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 ALK 320/4885IGF1R 606/4885CDK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.